We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+3.76%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$910M
AUM Growth
-$281M
Cap. Flow
-$283M
Cap. Flow %
-31.16%
Top 10 Hldgs %
40.89%
Holding
141
New
25
Increased
18
Reduced
31
Closed
51

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$27.6M
2
AMZN icon
Amazon
AMZN
+$13.8M
3
FIVN icon
FIVE9
FIVN
+$12.7M
4
SNY icon
Sanofi
SNY
+$11.9M
5
S icon
SentinelOne
S
+$11.7M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$47.9M
2
PFE icon
Pfizer
PFE
+$43.5M
3
ABBV icon
AbbVie
ABBV
+$15.6M
4
AZN icon
AstraZeneca
AZN
+$13.9M
5
JNJ icon
Johnson & Johnson
JNJ
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 68.66%
2 Technology 9.03%
3 Consumer Discretionary 4.71%
4 Communication Services 2.8%
5 Industrials 2.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
51
IDEAYA Biosciences
IDYA
$3.42B
$5.57M 0.61%
235,695
-58,924
-20% -$1.37M
PERI icon
52
Perion Network
PERI
$375M
$5.41M 0.59%
+225,000
New +$5.49M
VRNA
53
DELISTED
Verona Pharma
VRNA
$5.38M 0.59%
801,256
– –
IOVA icon
54
Iovance Biotherapeutics
IOVA
$1.82B
$5.38M 0.59%
281,769
-213,040
-43% -$4.69M
PMVP icon
55
PMV Pharmaceuticals
PMVP
$59.2M
$4.4M 0.48%
190,525
– –
STRO icon
56
Sutro Biopharma
STRO
$401M
$4.19M 0.46%
28,170
-1,313
-4% -$235K
KALV
57
DELISTED
KalVista Pharmaceuticals
KALV
$4.18M 0.46%
+316,200
New +$5.03M
NAUT icon
58
Nautilus Biotechnolgy
NAUT
$124M
$4.14M 0.46%
800,000
– –
ALLT icon
59
Allot
ALLT
$372M
$4.05M 0.45%
340,912
-155
-0% -$2.03K
OMGA
60
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$4M 0.44%
352,948
-175,000
-33% -$3.33M
BCAB icon
61
BioAtla
BCAB
$5.46M
$3.53M 0.39%
3,600
-686
-16% -$877K
CAMT icon
62
Camtek
CAMT
$6.18B
$3.45M 0.38%
+75,000
New +$3.19M
PNT
63
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$3.32M 0.36%
592,592
-146,598
-20% -$1.1M
TPTX
64
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$3.28M 0.36%
+68,734
New +$3.07M
BIIB icon
65
Biogen
BIIB
$30B
$3.12M 0.34%
+13,000
New +$3.34M
ONCR
66
DELISTED
Oncorus, Inc.
ONCR
$3.01M 0.33%
571,204
-309,498
-35% -$2.4M
INBX
67
DELISTED
Inhibrx, Inc. Common Stock
INBX
$2.71M 0.3%
61,931
-248,146
-80% -$9.92M
ACET icon
68
Adicet Bio
ACET
$85.2M
$2.62M 0.29%
+9,375
New +$1.61M
OTMO
69
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
$2.43M 0.27%
39,577
-423
-1% -$26.8K
CMPX icon
70
Compass Therapeutics
CMPX
$344M
$2.22M 0.24%
+700,000
New +$2.32M
BLSA
71
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.13M 0.23%
216,250
-471,650
-69% -$4.67M
AYLA
72
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$2.13M 0.23%
+250,000
New +$2.48M
QURE icon
73
CALL
uniQure
QURE
$3.03B
$2.07M 0.23%
100,000
– –
BGMS
74
Bio Green Med Solution Inc
BGMS
$4.91M
$1.98M 0.22%
141
– –
ARYE
75
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$1.94M 0.21%
200,000
– –
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2021 Portfolio in Review

As of Q4 2021, Sphera Funds Management held 141 positions worth $910M, down 24% from $1.19B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Sphera Funds Management withdrew a net $283M in Q4 2021, closing 51 positions and reducing 31 holdings. Its most notable exit was SolarEdge, an estimated $13.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 63% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Merck worth $26.6M.

  • Sphera Funds Management's largest Q4 2021 buy was Merck: 346,423 shares worth $26.6M.
  • Sphera Funds Management added most to Amazon in Q4 2021, an estimated $13.8M increase.
  • Sphera Funds Management's biggest Q4 2021 reduction was Eli Lilly, cutting an estimated $47.9M.
  • Sphera Funds Management fully exited SolarEdge in Q4 2021, selling an estimated $13.3M.
  • Sphera Funds Management's ten largest holdings make up 41% of its $910M portfolio in Q4 2021.
  • Sphera Funds Management opened 25 new positions and closed 51 in Q4 2021.
  • Sphera Funds Management's portfolio value fell 24% quarter-over-quarter to $910M.

Based on Sphera Funds Management's 13F filing for Q4 2021, filed 14 Feb 2022.